Gilead 4th-qtr sales and earnings beat forecasts, but slammed for "greed" by AHF
USA-based Gilead Sciences (Nasdaq: GILD), the leading maker of HIV/AIDS drugs, yesterday posted financial results, showing that total revenues for the fourth quarter of 2012 increased 18% to $2.59 billion, exceeding analysts’ expectations of $2.43 billion, according to Thomson Reuters I/B/E/S.
Net income for the quarter was $762.5 million, or $0.47 per diluted share compared to $665.1 million, or $0.43 per diluted share for the fourth quarter of 2011. Non-GAAP net income for the quarter, which excludes acquisition-related, restructuring and stock-based compensation expenses, rose 10.8% to $823.4 million, or $0.50 per diluted share compared to $743.1 million, or $0.49.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze